About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

NCT01026233·9 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Seagen Inc.

With

Millennium Pharmaceuticals, Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Relapsed or refractory CD30-positive malignancy
Adequate organ function
ECOG performance status \<2

You may not be if

Cardiac abnormalities (abnormal rhythm, history of significant cardiac event)
Current diagnosis of primary cutaneous ALCL
Acute or chronic graft-versus-host disease
Prior hematopoietic stem cell transplant within specified timeframe

The record

StatusCompleted

PhasePhase 1

Taking part52

StartedJan 2010

UpdatedDec 12, 2014

Conditions

Disease, Hodgkin Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin

Where9

University of Alabama at Birmingham
Birmingham, Alabama, United States
City of Hope National Medical Center
Duarte, California, United States
Stanford Cancer Center
Stanford, California, United States

Clareo Health | Cardiac Safety Study of Brentuximab Vedotin (SGN-35)